Roche Holding AG (SWX:RO)
293.40
-1.80 (-0.61%)
Oct 21, 2025, 5:31 PM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B
Revenue Growth
+4.80%
P/S Ratio
3.79
Revenue / Employee
614.90K
Employees
103,249
Market Cap
240.79B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Sandoz Group AG | 8.42B |
Alcon | 7.97B |
Lonza Group AG | 7.09B |
Galenica AG | 4.03B |
Sonova Holding AG | 3.87B |
Galderma Group AG | 3.73B |
Roche Holding AG News
- 10 hours ago - Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 14 hours ago - Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow - Seeking Alpha
- 19 hours ago - Top 3 Health Care Stocks You'll Regret Missing In October - Benzinga
- 1 day ago - FDA Approves Roche's Gazyva for Lupus Nephritis - GuruFocus
- 1 day ago - My Top 3 Pharma Stocks - Seeking Alpha
- 1 day ago - Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche - Investor's Business Daily
- 1 day ago - 'Why the world is falling to bits?': Roche on his upcoming book - CNBC
- 2 days ago - Roche's Gazyva Gets FDA Approval for Lupus Nephritis - WSJ